Exclusive video interview with Dave Asprey

We talk supplementation, neurotech, mitochondrial dysfunction, clinical scale-ups, COVID and CGM with Longevity legend: Dave Asprey

Ahead of Revolution Against Aging and Death conference, which starts today, we caught up with biohacking legend, entrepreneur and Longevity thought-leader: Dave Asprey.

Longevity.Technology: This is a great interview and worthy of 25 minutes of your time – Dave always delivers, but in this wide-ranging interview he shares thoughts on Elon Musk’s Neuralink, next-generation neurotech, CGM (continuous glucose monitoring) and we learn Dave’s top three tips for kick-starting your Longevity journey today:

We’ll be at RAADfest (as First Longevity): will you? Stop by our virtual booth (#515) and say ‘hi’ … PLUS: save $50 off admission by using our discount code: ‘longevity’ … boom!



Phil Newman
Editor-in-Chief Phil is Editor-in-Chief Longevity.Technology and founder of Crowd Longevity a digital investment platform for international investors and Longevity start-ups launching in 2020.

In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.

Latest articles

Epigenetic regulation of protein homeostasis following DNA damage

Recent study identifies critical regulator of protein biosynthesis recovery and homeostasis required for Longevity. Unresolved DNA damage caused by intrinsic and environmental factors accumulates during...

Deep Longevity and Longenesis collaborate to clock aging

Start the clock to stop the clock – centralised data will aid Longevity research.  Deep Longevity, which engages in the development of explainable AI systems...

Big Brother approach to accelerate preclinical studies

Tracked.bio develops AI computer vision system that tracks flies and mice to reduce man-hours and increase data collected in Longevity studies. A Danish start-up aims...

Astellas to acquire iota Biosciences

Following an R&D collaboration that began last year, Japanese pharma Astellas has announced it will acquire bioelectronics firm iota in $304m deal. Last year's R&D...